scholarly journals Spillover of West Caucasian Bat Lyssavirus (WCBV) in a Domestic Cat and Westward Expansion in the Palearctic Region

Viruses ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2064
Author(s):  
Stefania Leopardi ◽  
Ettore Barneschi ◽  
Giuseppe Manna ◽  
Barbara Zecchin ◽  
Pamela Priori ◽  
...  
Keyword(s):  
Urban Areas ◽  
Neutralizing Antibodies ◽  
Control Measures ◽  
Domestic Cat ◽  
Post Exposure Prophylaxis ◽  
Potential Hazard ◽  
Westward Expansion ◽  
Reference Isolate ◽  
Source Of Infection ◽  
Exposure Prophylaxis

In June 2020, a cat from Arezzo (Italy) that died from a neurological disease was diagnosed with West Caucasian Bat Lyssavirus (WCBV). The virus retained high identity across the whole-genome with the reference isolate found in 2002 from a Russian bent-winged bat. We applied control measures recommended by national regulations, investigated a possible interface between cats and bats using visual inspections, bioacoustics analyses and camera trapping and performed active and passive surveillance in bats to trace the source of infection. People that were exposed to the cat received full post-exposure prophylaxis while animals underwent six months of quarantine. One year later, they are all healthy. In a tunnel located near the cat’s house, we identified a group of bent-winged bats that showed virus-neutralizing antibodies to WCBV across four sampling occasions, but no virus in salivary swabs. Carcasses from other bat species were all negative. This description of WCBV in a non-flying mammal confirms that this virus can cause clinical rabies in the absence of preventive and therapeutic measures, and highlights the lack of international guidelines against divergent lyssaviruses. We detected bent-winged bats as the most probable source of infection, testifying the encroachment between these bats and pets/human in urban areas and confirming free-ranging cats as potential hazard for public health and conservation.

Chapter 14: Prevention: vaccines and immunoglobulins

2021 ◽  
Author(s):  
Eva-Maria Pöllabauer ◽  
Herwig Kollaritsch
Keyword(s):  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Western Europe ◽  
Surrogate Marker ◽  
Booster Vaccination ◽  
Post Exposure Prophylaxis ◽  
Pediatric Formulation ◽  
The One ◽  
Exposure Prophylaxis

Worldwide there are 6 different TBE vaccines – two from Western Europe, three from Russia and one from China. The two western European vaccines and one of the Russian vaccines have an adult and a pediatric formulation. The products names are FSME IMMUN and FSME-IMMUN Junior; Encepur adults and Encepur children, Klesch-E-Vac, EnceVir and EnceVir Neo, Dry lyophilized TBE Moscow and Sen Tai Bao. All TBE vaccines except the one from China have similar but not identical immunization schedules with primary immunization (>3 doses) and regular booster vaccinations. For FSME-IMMUN, Encepur and EnceVir rapid immunization schedules are also licensed. The Chinese vaccine is given with 2 primary doses 2 weeks apart followed by annual boosters. All vaccines induce significant immune responses. In the absence of a formal correlate of protection, the presence of neutralizing antibodies is used as a surrogate marker for protection. Recent clinical studies show long-term seropersistence of TBE antibodies after the first booster vaccination (dose 4) with the two European vaccines. An effectiveness of approximately 99% (years 2000–2006) and 98.7% (years 2000-2011) was calculated for regularly vaccinated persons in Austria, a country with established high vaccination uptake. Whereas in Western Europe post-exposure prophylaxis with immunoglobulins was discontinued in the late 1990s, in the highly endemic regions of Russia it continues to be common practice. Both – FSME-IMMUN and Encepur are well tolerated with a well-established safety profile. TBE-Moscow and EnceVir appear to be somewhat more reactogenic.

scholarly journals A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques

2021 ◽  
Author(s):  
Ronald R. Cobb ◽  
Joseph Nkolola ◽  
Pavlo Gilchuk ◽  
Abishek Chandrashekar ◽  
Robert V. House ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Rhesus Macaques ◽  
Human Monoclonal Antibody ◽  
Neutralizing Antibody ◽  
Post Exposure Prophylaxis ◽  
Human Mabs ◽  
Viral Neutralization ◽  
Exposure Prophylaxis ◽  
Human Primate

Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention, post-exposure prophylaxis, or therapy. However, the titer of neutralizing antibodies required for protection against SARS-CoV-2 infection remains poorly characterized. We previously described two potently neutralizing mAbs COV2-2130 and COV2-2381 targeting non-overlapping epitopes on the receptor-binding domain of SARS-CoV-2 spike protein. Here, we engineered the Fc-region of these mAbs with mutations to extend their persistence in humans and reduce interactions with Fc gamma receptors. Passive transfer of individual or combinations of the two antibodies (designated ADM03820) given prophylactically by intravenous or intramuscular route conferred virological protection in a non-human primate (NHP) model of SARS-CoV-2 infection, and ADM03820 potently neutralized SARS-CoV-2 variants of concern in vitro. We defined 6,000 as a protective serum neutralizing antibody titer in NHPs against infection for passively transferred human mAbs that acted by direct viral neutralization, which corresponded to a concentration of 20 microgram/mL of circulating mAb.

Chapter 14: Prevention – Vaccines + Immunoglobulins

2019 ◽  
Author(s):  
Eva-Maria Pöllabauer ◽  
Herwig Kollaritsch
Keyword(s):  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Western Europe ◽  
Surrogate Marker ◽  
Booster Vaccination ◽  
Post Exposure Prophylaxis ◽  
Pediatric Formulation ◽  
The One ◽  
Exposure Prophylaxis

• Worldwide there are 6 different TBE vaccines – two from Western Europe, three from Russia and one from China. The two western European vaccines and one of the Russian vaccines have an adult and a pediatric formulation. • The products names are FSME IMMUN and FSME-IMMUN Junior; Encepur adults and Encepur children, Klesch-E-Vac, EnceVir and EnceVir Neo, Dry lyophilized TBE Moscow and Sen Tai Bao • All TBE vaccines except the one from China have similar but not identical immunization sched-ules with primary immunization (>3 doses) and regular booster vaccinations. For FSME-IMMUN, Encepur and EnceVir a rapid immunization schedules is also licensed. The Chinese vaccine is giv-en with 2 primary doses 2 weeks apart followed by annual boosters. • All vaccines induce significant immune responses. In the absence of a formal correlate of pro-tection, the presence of neutralizing antibodies is used as a surrogate marker for protection. • Recent clinical studies show long-term seropersistence of TBE antibodies after the first booster vaccination (dose 4) with the two European vaccines. • An effectiveness of approximately 99% (years 2000–2006) and 98,7% (years 2000-2011) was calculated for regularly vaccinated persons in Austria, a country with established high vaccina-tion uptake. • Whereas in Western Europe post-exposure prophylaxis with immunoglobulins was discontinued in the late 1990s, in the highly endemic regions of Russia it continues to be common practice. • Both - FSME-IMMUN and Encepur are well tolerated with a well-established safety profile. TBE-Moscow and EnceVir appear to be somewhat more reactogenic.

scholarly journals An outbreak of influenza A(H1N1)v in a boarding school in South East England, May-June 2009

2009 ◽  
Vol 14 (27) ◽  
Author(s):  
A Smith ◽  
S Coles ◽  
S Johnson ◽  
L Saldana ◽  
C Ihekweazu ◽  
...  
Keyword(s):  
Influenza A ◽  
Boarding School ◽  
School Closure ◽  
Control Measures ◽  
Post Exposure Prophylaxis ◽  
Active Case Finding ◽  
School Population ◽  
Influenza A H1n1 ◽  
South East England ◽  
Exposure Prophylaxis

An outbreak of influenza A(H1N1)v was confirmed in May and June 2009 in a boarding school in South East England involving 102 symptomatic cases with influenza-like illness. Influenza A(H1N1)v infection was laboratory-confirmed by PCR in 62 pupils and one member of staff. Control measures were implemented as soon as a case was confirmed and included school closure, active case finding and treatment as well as post-exposure prophylaxis offered to the entire school population. Had the outbreak had been detected earlier, the school closed earlier and prophylaxis commenced after the initial cases were detected, we may have seen lower levels of transmission.

Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications

2019 ◽  
Vol 19 (3) ◽  
pp. 213-223 ◽  
Author(s):  
Binbin Hong ◽  
Yumei Wen ◽  
Tianlei Ying
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Neutralizing Antibodies ◽  
Recent Progress ◽  
Hbv Infection ◽  
Post Exposure Prophylaxis ◽  
Promising Alternative ◽  
B Virus ◽  
Hepatitis B Immunoglobulin ◽  
Exposure Prophylaxis

Background:Hepatitis B virus (HBV) infection remains a global health problem. As “cure” for chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized for several decades to provide post-exposure prophylaxis.:In recent years, a number of monoclonal antibodies (mAbs) targeting HBV have been developed and demonstrated with high affinity, specificity, and neutralizing potency.Objective:HBV neutralizing antibodies may play a potentially significant role in the search for an HBV cure. In this review, we will summarize the recent progress in developing HBV-neutralizing antibodies, describing their characteristics and potential clinical applications.Results and Conclusion: :HBV neutralizing antibodies could be a promising alternative in the prevention and treatment of HBV infection. More importantly, global collaboration and coordinated approaches are thus needed to facilitate the development of novel therapies for HBV infection.

scholarly journals COVID-19 Convalescent Plasma Is More Than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors

Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1594
Author(s):  
Daniele Focosi ◽  
Massimo Franchini ◽  
Liise-anne Pirofski ◽  
Thierry Burnouf ◽  
DeLisa Fairweather ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Neutralizing Antibodies ◽  
Randomized Clinical Trials ◽  
Neutralizing Antibody ◽  
Causal Link ◽  
Fresh Frozen Plasma ◽  
Post Exposure Prophylaxis ◽  
Fresh Frozen ◽  
Antibody Effects ◽  
Exposure Prophylaxis

COVID-19 convalescent plasma (CCP) is currently under investigation for both treatment and post-exposure prophylaxis. The active component of CCP mediating improved outcome is commonly reported as specific antibodies, particularly neutralizing antibodies, with clinical efficacy characterized according to the level or antibody affinity. In this review, we highlight the potential role of additional factors in CCP that can be either beneficial (e.g., AT-III, alpha-1 AT, ACE2+ extracellular vesicles) or detrimental (e.g., anti-ADAMTS13, anti-MDA5 or anti-interferon autoantibodies, pro-coagulant extracellular vesicles). Variations in these factors in CCP may contribute to varied outcomes in patients with COVID-19 and undergoing CCP therapy. We advise careful, retrospective investigation of such co-factors in randomized clinical trials that use fresh frozen plasma in control arms. Nevertheless, it might be difficult to establish a causal link between these components and outcome, given that CCP is generally safe and neutralizing antibody effects may predominate.

Chapter 14: Prevention: vaccines and immunoglobulins

2020 ◽  
Keyword(s):  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Western Europe ◽  
Surrogate Marker ◽  
Booster Vaccination ◽  
Post Exposure Prophylaxis ◽  
Pediatric Formulation ◽  
The One ◽  
Exposure Prophylaxis

Worldwide there are 6 different TBE vaccines – two from Western Europe, three from Russia and one from China. The two western European vaccines and one of the Russian vaccines have an adult and a pediatric formulation. The products names are FSME IMMUN and FSME-IMMUN Junior; Encepur adults and Encepur children, Klesch-E-Vac, EnceVir and EnceVir Neo, Dry lyophilized TBE Moscow and Sen Tai Bao All TBE vaccines except the one from China have similar but not identical immunization schedules with primary immunization (>3 doses) and regular booster vaccinations. For FSME-IMMUN, Encepur and EnceVir rapid immunization schedules are also licensed. The Chinese vaccine is given with 2 primary doses 2 weeks apart followed by annual boosters. All vaccines induce significant immune responses. In the absence of a formal correlate of protection, the presence of neutralizing antibodies is used as a surrogate marker for protection. Recent clinical studies show long-term seropersistence of TBE antibodies after the first booster vaccination (dose 4) with the two European vaccines. An effectiveness of approximately 99% (years 2000–2006) and 98.7% (years 2000-2011) was calculated for regularly vaccinated persons in Austria, a country with established high vaccination uptake. Whereas in Western Europe post-exposure prophylaxis with immunoglobulins was discontinued in the late 1990s, in the highly endemic regions of Russia it continues to be common practice. Both – FSME-IMMUN and Encepur are well tolerated with a well-established safety profile. TBE-Moscow and EnceVir appear to be somewhat more reactogenic.

scholarly journals Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

2020 ◽  
Vol 5 (1) ◽  
pp. 40 ◽  
Author(s):  
Thomas Moulenat ◽  
Céline Petit ◽  
Valérie Bosch Castells ◽  
Guy Houillon
Keyword(s):  
Systematic Review ◽  
Vero Cell ◽  
Rabies Virus ◽  
Neutralizing Antibodies ◽  
Rabies Vaccine ◽  
Post Exposure Prophylaxis ◽  
Post Exposure ◽  
Exposure Prophylaxis ◽  
Rabies Prevention ◽  
Rabies Vaccination

The purified Vero cell rabies vaccine (PVRV; Verorab®, Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1–3-site, 1–3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90–100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14–28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.

scholarly journals Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial

2021 ◽  
Author(s):  
Devang Parikh ◽  
Alok Chaturvedi ◽  
Naman Shah ◽  
Piyush Patel ◽  
Ronak Patel ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Pediatric Population ◽  
Severe Disease ◽  
Ordinal Scale ◽  
Post Exposure Prophylaxis ◽  
Rt Pcr ◽  
Early Improvement ◽  
Suitable Treatment ◽  
Immunocompromised State ◽  
Exposure Prophylaxis

Background COVID-19 hyper-immune globulin (HIG) solution is a human plasma-derived, highly-purified, concentrated, virus-inactivated preparation of neutralizing antibodies (NAbs) against COVID-19. Methods This was a randomized, two-arm, controlled, multi-center trial to evaluate the efficacy and safety of COVID-19 HIG in patients who were hospitalized with moderate-severe COVID-19 infection. Results A total of 60 patients were randomized (30 in each arm). Overall, COVID-19 HIG was well-tolerated without any serious treatment-emergent adverse event or tolerability issue. The mean change in ordinal scale by day 8 was 1.7±1.61 in the test arm vs. 2.0±1.68 in the control arm (mITT; p=0.367). Early and high NAbs were observed in the test arm compared to the control arm. More patients had negative RT-PCR by day 3 for the test arm vs. the control arm (mITT: 46.67% in test vs. 37.93% in control). The median time to be RT-PCR negative was 5.5 days for the test arm vs. 8.0 days for the control arm for PP population. Patients receiving COVID-19 HIG showed early improvement (reduction) in the biomarkers (CRP, IL-6, and D-dimer). Conclusion COVID-19 HIG was found to be safe and well-tolerated. Early and high NAbs were achieved in COVID-19 HIG recipients qualifying the product as a suitable treatment option, particularly in an immunocompromised state. It should be given early in infection to mitigate progression to severe disease. It should be evaluated for post-exposure prophylaxis as well as for prevention (where a vaccine is not suitable or effective). It should be evaluated in the pediatric population as well.

scholarly journals Current issues and gaps in the implementation of rabies prevention in Ukraine in recent decades

2021 ◽  
Vol 12 (2) ◽  
pp. 251-259
Author(s):  
I. F. Makovska ◽  
T. M. Krupinina ◽  
V. V. Nedosekov ◽  
T. M. Tsarenko ◽  
Y. A. Novohatniy ◽  
...  
Keyword(s):  
Public Awareness ◽  
Control Measures ◽  
Farm Animals ◽  
Annual Reports ◽  
Human Rabies ◽  
Future Research ◽  
Post Exposure Prophylaxis ◽  
Exposure Prophylaxis ◽  
Domestic Carnivores ◽  
Rabies Prevention

Ukraine remains the only country in Europe where rabies is widespread among animals and humans. Annually there are about 1,600 rabies cases in animals in Ukraine and sporadic cases in humans have been registered despite the conducting of preventive measures. Therefore, the aim of the study was to inspect the failures in rabies prevention, indicate the top reasons for human cases and highlights the risk of animal attacks in view of their species and geographical distribution in Ukraine during 1996–2020. The following archival state materials were used for analysis: from the Ministry of Health of Ukraine and from the annual reports of oblast departments of the State Service of Ukraine for Food Safety and Consumer Protection. In general, more than 84,000 people (187.4 per 100,000 of the population) were affected by bites or harmful contact with animals every year, among them, 2,155 people were victims of rabid animals. Post-exposure prophylaxis (PEP) was prescribed annually, on average, for 21,434 patients (25.5% of all victims). Most people were attacked by cats and dogs that had owners (71.5%). The frequency of the proportion of the risk of attacks by rabid dogs on humans was (1:124), from cats (1:25), wild animals (1:7), and farm animals (1:2), but the largest general proportion of animal attacks on people was from dogs – 838,635 attacks (77.7%). Thus, due to the permanently higher level of contact with people, attacks by dogs remains more dangerous. Geographically attacks on humans by domestic carnivores were observed most commonly in the east part of Ukraine due to the high urbanization of the region and the high density of the human population. A large number of attacks by foxes was observed in the west part of Ukraine due to the larger area of forests and fields. During the last 25 years, there have been 63 human rabies cases. The main sources of rabies were dogs (24 cases) and cats (22 cases). The main causes of development of rabies were: failure to receive the PEP due to the absence of a visit to a hospital after an attack of an animal (n = 38), failures in prescribing PEP (n = 15), failure of PEP (n = 10). In conclusion, the gaps in the control measures against rabies are the lack of agreed coordination of inter-sectoral links, the lack of significant efforts to raise public awareness and the lack of funding for prophylaxis programmes for humans and animals. Our future research will be aimed at modelling the transmission of rabies from the pet population to humans.

Sign in / Sign up

Export Citation Format

Share Document